Erman Akkus: Should up-front SRS be added to TKI in brain metastatic EGFR/ALK positive NSCLC?

Erman Akkus, Medical Oncologist at Ankara University, shared a paper by Luke R.G. Pike et al. on X:

“Should up-front SRS be added to TKI in brain metastatic EGFR/ALK+ NSCLC?

• Improves time-to-CNS progression HR: 0.63 (0.42 to 0.96), P = .033
• No difference in OS
• More than 20% of patients had >11 brain metastases.”

Source: Erman Akkus/X

Authors: Luke R.G. Pike, Emily Miao, Lillian A. Boe, Tejas Patil, Brandon S. Imber, Nathaniel J. Myall, Erqi L. Pollom, Caressa Hui, Vera Qu, Jacob Langston, Veronica Chiang, Michael Grant, Sarah B. Goldberg, Joshua D. Palmer, Rahul N. Prasad, Tony J.C. Wang, Albert Lee, Catherine A. Shu, Lanyi Nora Chen, Nicholas J. Thomas, Steve E. Braunstein, Brian D. Kavanagh, D. Ross Camidge, Chad G. Rusthoven

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)